• Curriculum Vitae
  • Teaching
  • Appointments
  • Research

Curriculum Vitae
Sergio Di Nuzzo, M.D., Ph.D.

Personal data:
name: Sergio
surname: Di Nuzzo
address: Via Volturno, 61
43125 Parma, Italy
telephone: +39 333 4928367
date of birth: May - 1st - 1962
place of birth: Pietramelara (CE), Italy
nationality: Italian

Present affiliation:

address: Section of Dermatology
University of Parma
Via Gramsci 14
43100 Parma
Italy
telephone: +39 0521 033562
fax: +39 0521 702323
e-mail: sergio.dinuzzo@ unipr.it

Education:

1996-2000 Ph.D., University of Amsterdam UVA, Amsterdam, The Netherlands.
1991-1995 Specialisation in Dermatology, University of Parma, Parma, Italy.
1982-1989 M.D. Diploma, University of Napoli Federico II, Napoli, Italy.

Fellowships, grants and additional training:

2002 One year Master-Allergology, University of Perugia, Perugia, Italy
1996 Three months fellowship supported by funds from the NUFFIC (Netherlands organisation for international co-operation in higher education). “Effects of UVB on cutaneous T cells”. Department of Dermatology, University of Amsterdam, Amsterdam, The Netherlands.
1994 Nine months fellowship supported by funds from the European Community ERASMUS Program. “Effects of solar-simulated UV light on cutaneous T cells”. Department of Dermatology, University of Amsterdam, Amsterdam, The Netherlands.
1990 One-year Master-Vascular disease, University of Napoli Federico II, Napoli, Italy.
Six months internship at the Department of Dermatology, Hospital of Caserta, Caserta, Italy.
1986-1989 Internship at the Department of Dermatology, University of Napoli Federico II.

Employment experiences:
2006-to date Permanent staff Member, Section of Dermatology, Department of Surgery, University of Parma.
2000- 2005 Postdoctoral Research Fellow, Department of Dermatology, University of Parma.
Private Practice, Dermatology
1996-2000 Research Fellow, Department of Dermatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
1991-1995 Resident in training, Department of Dermatology, University of Parma.
1990-1991 General Practitioner, Caserta, Italy.

Teaching experiences:
2006- to date Lecturer, Dermatology, School of Medicine, University of Parma.
Lecturer, Dermatology, School of Dentistry, University of Parma.
Lecturer, Skin biotechnology, School of Biotechnology, University of Parma
2000- 2006 Lecturer, Photoimmunodermatology, Department of Dermatology, University of Parma.
Resident and Student Tutor, Department of Dermatology, University of Parma.
1996-2000 Student Tutor, Photoimmunology Group, Department of Dermatology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
1990-1991 Lecturer, Normal Human Anatomy, Nurses School of Caserta, Caserta, Italy.

Publications:
1. Merante S, Ferretti VV, Elena C, Brazzelli V, Zanotti R, Ner I, Magliacane D, Belloni Fortina A, Ingeborg F, Pastorello EA, Pieri L, Papayannidis C, Mauro M, Grifoni F, Minelli R, Guggiari E, Difonzo E, Bocchia M, Caroppo F, Di Nuzzo S, Elli EM, Rondoni M, Ciccocioppo R, Stefano MD, Bossi G, Boveri E, Bonadonna P, Giona F, Valent P, Triggiani M. The Italian Mastocytosis Registry: 6-year experience from a hospital-based registry. Future Oncol. 2018, 12. doi:10.2217/fon-2018-0291. PMID: 30207489.

2. Martini S, Pozzi G, Carubbi C, Masselli E, Galli D, Di Nuzzo S, Banchini A, Gobbi G, Vitale M, Mirandola P. PKCε promotes human Th17 differentiation: Implications in the pathophysiology of psoriasis. Eur J Immunol. 2018 ;48:644-654. doi: 10.1002/eji.201747102. PubMed PMID:29280140.

3. Martini D, Angelino D, Cortelazzi C, Zavaroni I, Bedogni G, Musci M, Pruneti C, Passeri G, Ventura M, Galli D, Mirandola P, Vitale M, Dei Cas A, Bonadonna RC, Di Nuzzo S, De Felici MB, Del Rio D. Claimed Effects, Outcome Variables and Methods of Measurement for Health Claims Proposed Under European Community Regulation 1924/2006 in the Framework of Maintenance of Skin Function. Nutrients. 2017, 22. doi: 10.3390/nu10010007.PubMed PMID:29271939;

4. Pagliarello C, Stanganelli I, Ricci R, Feliciani C, Di Nuzzo S. A Pinkish-Blue Exophytic Nodule on the Arm of an Elderly Man: A Quiz. Acta Derm Venereol. 2017 Jun 29. doi: 10.2340/00015555-2740. [Epub ahead of print] PubMed PMID: 28660282.

5. Pagliarello C, Fabrizi G, De Felici B, Casanova D, Feliciani C, Di Nuzzo S. Notalgia paresthetica: factors associated with its perceived severity, duration, side, and localization. Int J Dermatol. 2017 Jun 23. doi: 10.1111/ijd.13666.[Epub ahead of print] PubMed PMID: 28646529.

6. Pagliarello C, Scrivani S, Fabrizi G, Feliciani C, Di Nuzzo S. An under-recognized, life-threatening complication of atopic dermatitis. Clin Exp Dermatol. 2017 Jun 9. doi: 10.1111/ced.13171. [Epub ahead of print] PubMed PMID: 28597997.

7. Martini D, Rossi S, Biasini B, Zavaroni I, Bedogni G, Musci M, Pruneti C, Passeri G, Ventura M, Di Nuzzo S, Galli D, Mirandola P, Vitale M, Dei Cas A, Bonadonna RC, Del Rio D. Claimed effects, outcome variables and methods of measurement for health claims proposed under European Community Regulation 924/2006 in the framework of protection against oxidative damage and cardiovascular health. Nutr Metab Cardiovasc Dis. 2017 Jun;27(6):473-503. doi:10.1016/j.numecd.2017.01.008. Epub 2017 Feb 13. Review. PubMed PMID: 28434807.

8. Pagliarello C, Fabrizi G, Ricci R, Besagni F, DE Felici B, Boccaletti V, Feliciani C, DI Nuzzo S. Acquired progressive hyperpigmentation. G Ital Dermatol Venereol. 2017 Jun;152(3):312-314. doi: 10.23736/S0392-0488.16.05195-6. PubMed PMID: 28409580.

9. Pagliarello C, Stanganelli I, Fabrizi G, Feliciani C, Di Nuzzo S. Digital Dermoscopy Monitoring: Is it Time to Define a Quality Standard? Acta Derm Venereol. 2017 Jul 6;97(7):864-865. doi: 10.2340/00015555-2663. PubMed PMID:28358167.

10. Pagliarello C, Cortelazzi C, Feliciani C, Di Nuzzo S. Secondary syphilis. Lancet Infect Dis. 2016 Nov;16(11):1304. doi: 10.1016/S1473-3099(16)30129-3.PMID:27788991

11. Pagliarello C, Peccerillo F, Zucchi A, Tortorella RG, Ricci R, Stanganelli I, Feliciani C, Di Nuzzo S. Lesion presenting with a "blue amber" pattern. World J Clin Cases. 2016 Oct 16;4(10):333-335.PMID:27803916

12. Pagliarello C, Stanganelli I, Fabrizi G, Feliciani C, Di Nuzzo S. Topical Diphencyprone Immunotherapy for Painful Nodular Acral Recurrence of Kaposi Sarcoma. JAMA Dermatol. 2016 Nov 30. doi: 10.1001/jamadermatol.2016.4301. [Epub ahead of print] PMID: 27902811

13. Pagliarello C, Stanganelli I, Zambito-Spadaro F, Feliciani C, Di Nuzzo S. Sex Differences in Axial and Limb Distribution of Melanocytic Naevi. Acta Derm Venereol. 2017 Feb 8;97(2):266-267. doi: 10.2340/00015555-2518. PubMed PMID:27545295.

14. Di Lernia V, Bonamonte D, Lasagni C, Belloni Fortina A, Cambiaghi S, Corazza M, Di Nuzzo S, Gisondi P, Panzone M, Guarneri C, Neri I. Effectiveness and Safety of Acitretin in Children with Plaque Psoriasis: A Multicenter Retrospective Analysis. Pediatr Dermatol. 2016; 33:530-5.

15. Pagliarello C, Feliciani C, Fantini C, Cortelazzi C, de Felici Del Giudice B, Di Nuzzo S. Use of the dermoscope as a smartphone close-up lens and LED annular macro ring flash. J Am Acad Dermatol 2016 ;75:e27-8.

16. Cappuccio A, Limonta T, Parodi A, Cristaudo A, Bugliaro F, Cannavò SP, Rossi O, Gurioli C, Vignoli A, Parente R, Iemoli E, Caldarola G, De Pità O, Di Nuzzo S, Cancian M, Potenza C, Caminati M, Stingeni L, Saraceno R, Trevisini S, Piccirillo A, Sciarrone C, Panebianco R, Gola M, Costanzo A, Grieco T, Massaroni K, Reale L, Marini MG. Living with Chronic Spontaneous Urticaria in Italy: A Narrative Medicine Project to Improve the Pathway of Patient Care. Acta Derm Venereol. 2016 Jun 8. doi: 10.2340/00015555-2478. [Epub ahead of print]

17. Ticinesi A, Meschi T, Lauretani F, Felis G, Franchi F, Pedrolli C, Barichella M, Benati G, Di Nuzzo S, Ceda GP, Maggio M. Nutrition and Inflammation in Older Individuals: Focus on Vitamin D, n-3 Polyunsaturated Fatty Acids and Whey Proteins. Nutrients. 2016 29;8:186.

18. Stanganelli I, Naldi L, Falcini F, Magi S, Mazzoni L, Medri M, Bertoncini R, Calderoni O, Agnoletti V, Nadiani L, Palmieri G, Di Nuzzo S, Pagliarello C, Gandini S.Parental Use and Educational Campaigns on Sunbed Use Among Teenagers and Adolescents. Medicine. 2016 ;95:e3034.

19. Di Lernia V, Neri I, Calzavara Pinton P, Di Nuzzo S, Stingeni L, Guarneri C,Belloni Fortina A, Bonamonte D, Cambiaghi S, Lasagni C, Panzone M, Corazza M, Offidani A, Gisondi P. Treatment patterns with systemic antipsoriatic agents in childhood psoriasis: an Italian database analysis. G Ital Dermatol Venereol. 2016 Jan 13. [Epub ahead of print] PubMed PMID: 26761766.

20. Pagliarello C, Fabrizi G, Di Nuzzo S. Cryoinsufflation for Hidradenitis Suppurativa: Technical Refinement to Prevent Complications. Dermatol Surg. 2016; 42:130-2.

21. Di Nuzzo S, Boccaletti V, Fantini C, Cortelazzi C, Missale G, Fabrizi G, Lotti T, Hercogová J, Pagliarello C. Are Anti-TNF-α Agents Safe for Treating Psoriasis in Hepatitis C Virus Patients with Advanced Liver Disease? Case Reports and Review of the Literature. Dermatology. 2015 Oct 8.

22. Pagliarello C, Fabrizi G, Ricci R, Tabolli S, Feliciani C, Di Nuzzo S. Side predominance of squamous cell carcinoma: further evidence. J Eur Acad DermatolVenereol. 2015 Apr 10. doi: 10.1111/jdv.13156. [Epub ahead of print] PubMed PMID: 25864957.

23. Boccaletti V, Cortelazzi C, Fantini C, Tognetti E, Fabrizi G, Pagliarello C, Di Nuzzo S. Acute generalized exanthematous pustulosis following paracetamol ingestion in a child. Pediatr Allergy Immunol. 2015; 26:391-2.

24. Pagliarello C, Fabrizi G, Fantini C, Cortelazzi C, Boccaletti V, Annessi G, Zampetti A, Feliciani C and Di Nuzzo S. Calcipotriol/Betamethasone dipropionate ointment compared with tacrolimus ointment for the treatment of erosive pustular dermatosis of the scalp: a split lesion comparison. Eur J Dermatol. 25:206-8, 2015.

25. Di Nuzzo S, Cortelazzi C, Boccaletti V, Zucchi A, Conti ML, Montanari P, Feliciani C, Fabrizi G, Pagliarello C. Comparative study of trichloroacetic acid versus photodynamic therapy with topical 5-aminolevulinic acid for actinic keratosis of the scalp. Photodermatol Photoimmunol Photomed. 31:233-8, 2015.

26. V. Boccaletti, G. Zambruno, D. Castiglia, C. Magnani, E. Tognetti, G. Fabrizi, C. Cortelazzi, C. Pagliarello, S. Di Nuzzo. Recessive bullous dermolysis of the newborn in preterm siblings with a missense mutation in type VII collagen. Pediatric Dermatology. 32:e42-7. 2015.

27. Pagliarello C, Fabrizi G, Cortellazzi C, Boccaletti V, Feliciani C, Di Nuzzo S. Psoriasis and seborrheic dermatitis in infancy and childhood. G Ital Dermatol Venereol. 149:683-91, 2014

28. Boccaletti V, Di Nuzzo S, Feliciani C, Fabrizi G, Pagliarello C. An update on juvenile dermatomyositis. G Ital Dermatol Venereol. 149: 519-24, 2014.

29. Colombo D, Chimenti S, Grossi P, Marchesoni A, Di Nuzzo S, Griseta V, Gargiulo A, Parodi A, Simoni L, Bellia G. Prevalence of past and reactivated viral infections and efficacy of cyclosporine A as monotherapy or in combination in patients with psoriatic arthritis--synergy study: a longitudinal observational study. Biomed Res Int. 2014:941767, 2014.

30. V. Boccaletti, S. Di Nuzzo. Images in clinical medicine. Linear IgA Bullous Disease. N Engl J Med. 370:2228, 2014.

31. Pagliarello C. Fabrizi G. Feliciani C. and Di Nuzzo S. Cryoinsufflation for Hurley stage II hidradenitis suppurativa: a useful treatment option when systemic therapies should be avoided. JAMA Dermatol. 150:765-6, 2014.

32. Gisondi P, Amerio P, Amoroso GF, Antonucci VA, Bardazzi F, Buongiorno MR, Bruni P, Campanati A, Caproni M, Carlesimo M, Carrera CG, Cianchino G, Cimmino G, Costanzo A, Cozzani E, Dapavo P, D'amico D, De Simone C, Del Giglio M, Di Nuzzo S, Gai F, Galluccio AG, Goffredo A, Gualdi G, Guarneri C, Kokelj F, Lasagni C, Loconsole F, Longo V, Malagoli P, Miracapillo A, Mugheddu C, Parodi A, Pellegrino M, Peserico A, Piaserico S, Pistone G, Potenza C, Plumari A, Stingeni L, Strippoli D, Travaglino M, Girolomoni G. [Optimization of systemic treatments for chronic plaque psoriasis. Recommendations for switching and transitioning.] G Ital Dermatol Venereol.148:1-10, 2013.

33. Pagliarello C, Pepe CA, Lombardi M, Feliciani C, Fabrizi G, Di Nuzzo S. Early miscarriage during Sweet’s syndrome: uncommon, but probably not coincidental. Eur J Dermatol. 23:707-708, 2013.

34. Di Nuzzo S, Ercolini E, Carrozzo E, Fante C, Casanova D, Pruneti C. Personality, Alexithymic and Autonomic Aspects in Psoriatic Patients: a preliminary Study. 2012. Clin Drug Invest. 33: S88-S90. 2013.

35. Di Nuzzo S, Casanova D, Boccaletti V, Zanni M. Safety of etanercept treatment in psoriatic patients with chronic hepatitis C infection. Clinical and virological study in five patients: preliminary data. 2012. Clin Drug Invest. 33:S80-S82, 2013.

36. D. Casanova, G. Martignoni, V. Boccaletti, S Di Nuzzo. Bowen’s disease in a renal transplant recipient treated with topical imiquimod: serious adverse skin reaction with favourable clinical outcome. Acta Biomed. 83:81-83, 2012.

37. Zanni M, Missale G, Santilli D, Di Nuzzo S. Etanercept in the treatment of psoriasis and psoriatic arthritis with concomitant hepatitis C virus infection: clinical and virological study in three patients. Eur J Dermatol. 21:564-567, 2011.

38. Di Nuzzo S, Masotti A. Depigmentation Therapy in vitiligo universalis with cryotherapy and 4-hydroxyanisole. Clin Exp Dermatol. 32:215-216, 2010

39. Di Nuzzo S, Pavanello P, Masotti A, Giordano G, De Panfilis G. Densities, distribution and phenotypic expression of T cells in human fetal skin. Arch Dermatol Res. 301:753-755, 2009

40. Di Nuzzo S, Pavanello P, De Panfilis G. Density and proportion of the epidermal T cell population in human sun-exposed skin differ from those in sun-protected skin: preliminary immunohistochemical study. Arch Dermatol Res. 301:219–226, 2009

41. Musolino A, Panebianco M, Zendri E, Santini M, Di Nuzzo S, and Ardizzoni A. Hypertriglyceridaemia with bexarotene in cutaneous T-cell lymphoma: The role of omega-3 fatty acids. Br J Haematol. 145:84-6, 2009.

42. Di Nuzzo S, Zanni M, De Panfilis G. Cutaneous ulceration induced by leflunomide in a psoriatic patient. Int J Dermatology. 48: 659–660, 2009

43. Di Nuzzo S., Zanni M., De Panfilis G.: Exacerbation of paranoid schizophrenia in a psoriatic patient after treatment with cyclosporine A, but not with etanercept. J Drug Dermatol. 6:1046-7, 2007

44. Di Nuzzo, S., Sylva-Steenland, R.M., Koomen, C.W., Nakagawa, S., van Breemen M., de Rie, M.A., Das, P.K., Bos, J.D. and Teunissen, M.B.M: In vivoUVB irradiation of normal human skin favors the development of type 2 T cell responses in primary dermal cell culture. Photochem. Photobiol.76:301-313, 2002.

45. Teunissen, M.B.M , Piskin, G., Di Nuzzo, S., Sylva-Steenland, R.M., de Rie, M.A. and Bos, J.D: Ultraviolet-B radiation induces a transient appearance of IL-4+ neutrophils, which support the development of Th2 responses. J Immunol. 168:3732-3739, 2002.

46. Di Nuzzo, S., Sylva-Steenland, R.M., Koomen, C.W., de Rie, M.A., Bos, J.D., Das, P.K., and Teunissen, M.B.M: Exposure to UVB induces accumulation of LFA-1+ T cells and enhanced expression of the chemokine psoriasin in normal human skin. Photochem. Photobiol. 72:374-382, 2000.

47. de Rie, M.A., Di Nuzzo, S., Brands, S., Hansen, A.B., and Bos, J.D: Calcipotriol ointment and cream or their vehicles applied immediately before irradiation inhibit ultraviolet B-induced erythema. Br. J. Dermatol. 142:1160-1165, 2000.

48. Di Nuzzo, S., Sylva-Steenland, R.M., de Rie, M.A., Das, P.K., Bos, J.D., and Teunissen, M.B.M: UVB radiation preferentially induces recruitment of memory CD4+ T cells in normal human skin: long-term effect after a single exposure. J. Invest. Dermatol. 110:978-981, 1998.

49. Di Nuzzo, S., de Rie, M.A., van der Loos, C.M., Bos, J.D., and Teunissen, M.B.M: Solar-simulated ultraviolet irradiation induces selective influx of CD4+ T lymphocytes in normal human skin. Photochem. Photobiol. 64:988-993, 1996.

Publications as a member of Study Groups:

50. Costanzo A, Bianchi L, Flori ML, Malara G, Stingeni L, Bartezaghi M, Carraro L, Castellino G; SUPREME Study Group: Di Nuzzo S, Parma. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. Br J Dermatol. 2018, 28. doi: 10.1111/bjd.16705. PubMed PMID: 29704432.

51. Colombo D, Banfi G, Cassano N, Graziottin A, Vena GA, Fiori GG, Zagni E, Stingeni L, Chimenti S, Berardesca E, Micali G, Albertini G, De Simone C, Bellia G; GENDER ATTENTION study group. (Di Nuzzo S, responsabile del centro di ricerca di Parma). The GENDER ATTENTION Observational Study: Gender and Hormonal Status Differences in the Incidence of Adverse Events During Cyclosporine Treatment in Psoriatic Patients. Adv Ther. 2017 Jun;34(6):1349-1363. doi: 10.1007/s12325-017-0526-7. Epub 2017 Apr 21. PubMed PMID: 28432647; PubMed Central PMCID: PMC5487861.

52. Gisondi P, Cazzaniga S, Chimenti S, Maccarone M, Picardo M, Girolomoni G, Naldi L; Psocare Study Group (Di Nuzzo S, Responsabile del Centro Psocare di Parma). Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare Registry. Br J Dermatol. 2015; 172:1613-20.

53. Piaserico S, Cazzaniga S, Chimenti S, Giannetti A, Maccarone M, Picardo M, Peserico A, Naldi L; Psocare Study Group (Di Nuzzo S, main investigator Psocare center of Parma). Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry. J Am Acad Dermatol. 70:257-262, 2014.

54. Reich K, Zschocke I, Bachelez H, de Jong EM, Gisondi P, Puig L, Warren RB, Mrowietz U; the TTOP study group (Di Nuzzo S, main investigator Center of Parma). Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study.results have been published in: Reich k et al. J Eur Acad Dermatol Venereol. 2014 Oct 26. doi: 10.1111/jdv.

55. P. Gisondi, S. Cazzaniga, S. Chimenti, A. Giannetti, M. Maccarone, M. Picardo G. Girolomoni, L. Naldi, and Psocare Study Group (Di Nuzzo S, main investigator Psocare Center of Parma). Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. J Eur Acad Dermatol Venereol. 27:e-30-41, 2013

56. Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD, Estojak J, Molta CT, Freundlich B and PRESTA Study Centers (Di Nuzzo S, main investigator Research Center of Parma). Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ. 340:c229, 2010

57. Naldi L, Addis A, Chatenoud L, Giannetti A, Picaro M, Tomino C, Rossi P, Cimenti S, Maccarone M, Caggese E, Cuscito R, Martini N and Psocare Study Centers (Di Nuzzo S, main investigator Psocare Center of Parma). Impact of body mass index and obesità on clinical response to systemic treatment for psoriasis. Evidence from the Psocare Project. Dermatology. 217:365–373, 2008

58. Finzi A, Colombo D, Caputo A, Andreassi L, Chimenti S, Vena G, Simoni L, Sgarbi S, Giannetti A and PSYCHAE Study Group (Di Nuzzo S, main investigator Research Center of Parma). Psychological distress and coping strategies in patients with psoriasis: the PSYCHAE Study. J Eur Acad Dermatol Venereol. 21:1161-9, 2007

59. Capezzera R, Zane C, Calzavara-Pinton PG and GIFDE (Di Nuzzo S. member of GIFDE). UVA 1 Phototherapy. G Ital di Dermatol Venereol. 141:257-65, 2006

60. Rossi R, Lotti T, Cappugi P, Sala R, Venturini M, Calzavara-Pinton PG and GIFDE (Di Nuzzo S, member of GIFDE): Guidelines for phothodynamic therapy in dermatology. G Ital Dermatol Venereol 140:637-44, 2005.

61. Giannetti A, Finzi A and AISP (Di Nuzzo S. membro del Gruppo di studio AISP): Terapia sequenziale della psoriasi a placche con l’associazione Calcipotriolo/Betametasone dipropionato (Dovobet) una volta al giorno, seguita da Calcipotriolo (Daivonex) due volte al giorno in 349 pazienti. Esperienze Dermatologiche-Dermatological Experences Vol. VII-No 3, 2005.

62. Finzi A, Colombo MD, Caputo A, Andreassi L, Chimenti S, Vena G, Simoni L, Sgarbi S, Riannetti A and PSYCHAE Study Group (Di Nuzzo S. membro del gruppo di studio PSYCHAE): Psychopatological status and coping strategies in psoriatic patients: objectives and methodology of the Psoriasis SurveY for the Control of Anxiety and dEpression (PSYCHAE) study. G Ital Dermatol Venereol 140:583-590, 2005.

Chapters Book

63. Pagliarello C, Fabrizi G, Feliciani C, Di Nuzzo S. “Hidradenitis Suppurativa” Chapter 88 in: W. Abramovits et al. (eds.) Dermatological Cryosurgery and Cryotherapy. Springer-Verlag London 2016

64. Di Nuzzo S. Fototerapia. In: Feliciani et al, Guida pratica di Dermatologia e Venereologia, pag.507-509. Editore: Piccin Nuova Libraria, Padova. I edizione, 2014. ISBN 978-88-299-2309-0.

65. Boccaletti V, Di Nuzzo S, Salsi B, De Panfilis G. Capitolo 1. Il sistema immunitario cutaneo in età pediatrica. In: Dermatologia Pediatrica e dell’ Adolescenza, pag:13-26. Editore: Lotti T. C.I.C. Edizioni Internazionali, Roma. 2009. ISBN 978-88-7141-841-4.

66. Cavani A., Di Nuzzo S., Girolomoni G. and De Panfilis G.: Lymphocyte Subpopulations of the Skin (Chapter 6). In: Skin Immune System (SIS), editor Bos J.D., CRC Press, Boca Raton, FA, Third edition, 2004.

Clinical Trials (as principal investigator):
2018 Studio “DIMESKIN 2”: studio clinico in aperto per valutare l’efficacia e la tollerabilità a lungo termine del trattamento con dimetilfumarato (DMF) in adulti affetti da psoriasi cronica a placche. Sponsor Galderma
Studio BMS-986165 :a Multi-Center,Randomized,Double-Blind,Placebo- and Active Comparator-Controlled Phase 3 study with an Introduction Period Followed by Randomized Maintenance Period to Evaluate the Clinical Efficacy and Safety of BMS-986165 IN Subjects with Moderate to Severe Psoriasis. Sponsor Brystol-Meyers Squibb
2017 Studio “CAIN457A2310”: a randomized,double- blind , placebo- and active controlled multicenter trial to demonstrate efficacy of subcutaneous secukinumab compared to placebo and Etanercept (in a single-blinded arm) after twelve weeks of treatment,and to assess the safety,tolerability,and long-term efficacy in subjects from 6 to less than 18 years of age with severe chronic plaque psoriasis”. Sponsor Pfeizer
2016 Studio”RD.06.SPR..18132”: studio multicentrico,randomizzato,in doppio cieco , a gruppi paralleli sulla sicurezza e l’efficacia di calcitriolo da 3mcg/g unguento verso veicolo , applicati due volte al giorno per 8 settimane in soggetti pediatrici (da 2 a 12 anni) affetti da psoriasi a placche da lieve a moderata. Sponsor Galderma.
2015 Studio “RD.06.SPR.18131”: studio multicentrico ,in aperto , non controllato per valutare l’efficacia e la sicurezza a lungo termine di calcitriolo unguento 3mcg/g applicato due volte al giorno per 26 settimane in soggetti pediatrici (2-17 anni) affetti da psoriasi a placche da lieve a moderata. Sponsor Galderma.
Studio “Cain457AIT01”: studio multicentrico,prospettico ,in aperto ,della durata di 24 settimane per valutare l’efficacia in termini di non inferiorità rispetto al tasso di risposta PASI 90 e il profilo di sicurezza di Secukinumab 300mg in pazienti Cw6-negativi e Cw6 positivi con psoriasi a placche cronica da moderata a severa. Sponsor Novartis.
2014 Studio “Vaccines and Diagnostics”: studio clinico di fase III, stratificato, randomizzato
controllato, in cieco per l’osservatore, e multicentrico finalizzato alla valutazione della sicurezza della tollerabilità e dell’immunogenicità di due dosi di AH5N1 somministrate a soggetti adulti anziani in presenza o meno di condizioni di immunosoppressione. Sponsor Novartis.
2013 Studio SCH900222/MK-3222: studio di fase 3 ,randomizzato con comparatore attivo, controllato verso placebo ,a disegno parallelo,della durata di 52 settimane per la valutazione dell’efficacia e della sicurezza/tollerabilità di tildrakizumab (SCH900222/MK-3222) SC, seguito da uno studio di estensione opzionale sulla sicurezza a lungo termine, in soggetti con psoriasi a placche cronica da moderata a grave. Sponsor Merck Sharp & Dohme Corporation.
2012 Studio randomizzato prospettico‘PSO-TOP’: Ottimizzazione della terapia ambulatoriale nella psoriasi lieve e moderata per mezzo di un “Programma di Terapia Topica” di nuova concezione - studio internazionale con Dovobet® Gel). Sponsor Leo Pharma. I risultati sono stai pubblicati in: Reich k et al. J Eur Acad Dermatol Venereol. 2014 Oct 26. doi: 10.1111/jdv
Studio osservazionale “IDIF”: “Studio osservazionale, prospettico, multicentrico sull’approccio terapeutico topico nella psoriasi del cuoio capelluto di grado lieve moderato”. Sponsor IDI.
Studio “ETANERCEPT cod.08881x1.4535WW”: studio randomizzato in aperto di confronto fra 2 strategie differenti nella gestione di soggetti con psoriasi a placche che hanno corrisposto al trattamento con ETANERCEPT. Sponsor Pfizer Italia.
2011 Studio osservazionale “GENDER ATTENTION”: La donna nella sua reale dimensione: l’effetto del genere e dell’assetto ormonale sull’incidenza di effetti collaterali in pazienti affetti da psoriasi a placche trattati con ciclosporina. Sponsor Novartis Farma.
2010 Studio osservazionale “SYNERGY”, Observational StudY of INfectious Events in PsoRiasis complicated bY Active Psoriatic Arthrithis. Sponsor Novartis. I risultati sono stati pubblicati in: Colombo D et al. Biomed Res Int. 2014:941767, 2014
2008 Studio “SCORE”, Sustained Ciclosporin Outcome Replacing Etanercept. Studio pilota randomizzato, multicentrico, in doppio cieco, controllato con placebo per valutare l’efficacia e la sicurezza di Etanercept in pazienti con psoriasi a placche da moderata a severa dopo la cessazione della terapia con ciclosporina. Sponsor Wyeth Lederle S.p.A. I risultati sono in corso di pubblicazione.
2007 Studio “PRESTA”, Psoriasis Randomized Etanercept Study in Subjects with Psoriatic Arthritis, Studio randomizzato, multicentrico, in doppio cieco, diviso in due periodi, per valutare l’efficacia e la sicurezza di Etanercept sulla malattia cutanea e articolare in soggetti psoriasici con artrite psoriasica. Sponsor Wyeth Lederle S.p.A. i risultati sono stati pubblicati in: Sterry W et al. BMJ 340:229, 2010.
2002 Studio “PSYCHAE”, Psoriasis SurveyY for the Control of tHe Anxiety and dEpression.. Sponsor Novartis. I risultati sono stati pubblicati in: Finzi et al. G Ital Dermatol Venereol 140:583, 2005; Finzi et al. J Eur Acad Dermatol Venereol 21:1161, 2007.

Major research interests:
1. Photoimmunology
2. Skin Cancer Immunosurveillance
3. Phototherapy
4. Psoriasis and Vitiligo
5. Clinical Photodermatology

Languages:
Italian: native speaker
English: fluent
Dutch: fair

........................................ date:....................

References available on request.

Completion accademic year: 2018/2019

Completion accademic year: 2017/2018

Completion accademic year: 2016/2017

Completion accademic year: 2015/2016

Completion accademic year: 2014/2015

Professor/Teacher

Teacher tutor

Ultime pubblicazioni:

Contacts

Phone number
033574